News

The expanded Indication now includes children of all ages with achondroplasia, the most common form of skeletal dysplasia leading to disproportionate short stature.

This interview featured a discussion with Dr. Bhatia on the future of actinic keratosis diagnosis and treatment, as well as advances and important facts for clinicians to remember about risk.

Mona Shahriari, MD, and Andrew F Alexis, MD, MPH, discussed the multifaceted considerations dermatologists should weigh when treating patients with skin of color diagnosed with plaque psoriasis.

24-month results from OAKS and DERBY show that pegcetacoplan significantly reduced GA lesion growth with both monthly and every-other-month dosing.

These findings, presented at the Fall Clinical Dermatology conference, resulted from the ADjoin long-term extension study.

The approval was announced by Zydus Life Sciences Limited in a press release on October 20, 2023.

Sex, age at disease onset, and psoriatic arthritis were associated with the greatest impact on major life-changing decisions in patients with psoriasis.

Exposure to maternal diabetes during pregnancy is associated with an increased risk of depression and anxiety in offspring later in life, according to a new study.

The real-world evidence study examined patients with PsA taking secukinumab and ixekizumab, highlighting 80% treatment persistence after 1 year.

This interview at the Fall Clinical Dermatology conference featured a discussion with Dr. Bhatia regarding key insights from his talk ‘What You Need To Know NOW About Actinic Keratosis.’

A convolutional neural network accurately predicted eyes that progressed from intermediate AMD to GA within 1 year using volumetric SD-OCT scans.

Susan C. Taylor, MD, emphasizes the importance of understanding the unique biological differences and needs of individuals with skin of color.

In this interview on the conference floor at Fall Clinical Dermatology, Dr. Lio discussed the important topic of treating patients with eczema that have skin of color.

Results of several clinical trials demonstrated the superior efficacy of risankizumab compared with apremilast or placebo.

This presentation at the Fall Clinical Dermatology conference in Las Vegas explored the topic of advancements in HS treatment.

Benjamin Lockshin, MD, explains the current landscape of oral medications for plaque psoriasis, emerging developments in treatment, and the importance of shared decision-making.

A 20 mg weekly oral dose of methotrexate shows potential as a low-cost treatment for reducing pain and stiffness in patients with symptomatic hand osteoarthritis, according to the results of the METHODS trial.

Although both anti-VEGFs maintain a consistent safety profile, aflibercept shows a more pronounced short-term inhibitory effect on inflammation after vitrectomy for diabetic retinopathy.

Final data from STARS Nutrition were presented at United European Gastroenterology Week 2023, demonstrating a significant reduction in parenteral support.

Bimekizumab was found to be more cost-effective than most biologics and targeted synthetic disease-modifying antirheumatic drugs in a Swedish healthcare system-based model.

This case report from Brady Pregerson, MD, features a woman in her mid-80s with a history of ASCVD admitted for intermittent chest pain. Check out the ECG and determine the correct diagnosis!

New cross-sectional research indicates factors influencing ocular lesion status can include diabetes status, prednisolone dosage, and systemic infection status after kidney transplantation.

An analysis of more 13,000 children with type 1 diabetes suggests puberty onset in children with type 1 diabetes is occurring earlier now than it had been at the turn of the century.

Results from the phase 3 NEAR-1 and NEAR-2 clinical trials show consistent efficacy and tolerability of the preservative-free, low-dose eye drop in patients with presbyopia.

Results from the phase 3 ATLANTIS study showed amitriptyline was superior to placebo across multiple symptom-based outcomes for patients with IBS.

The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

Results demonstrated a low persistence rate for apremilast among patients with PsA, highlighting a notable barrier to treatment success.

In the PROTECT trial, teplizumab preserved β-cell function in newly diagnosed type 1 diabetes patients, slowing the decline of C-peptide levels, but key secondary endpoints, such as time in range and HbA1c, showed numerical trends without statistical significance.

Achievement of minimal disease activity and remission were observed in approximately half of patients with psoriatic arthritis receiving upadacitinib.

On October 17, 2023, Ardelyx Inc announced the FDA approval of tenapanor (Xphozah) for reducing serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy.